Search - tctmd.com

Displaying 181 - 200 of 511

Sort: Relevancy | Date

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

News Daily News

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

January 23, 2019

Guidelines for Peripheral Interventions Often Built on Shaky Foundation

News Daily News

Guidelines for Peripheral Interventions Often Built on Shaky Foundation

January 10, 2019

DES for Femoropopliteal Disease: IMPERIAL

Podcast TCTMD Talking Points

DES for Femoropopliteal Disease: IMPERIAL

January 09, 2019

AHA Scientific Statement: Get PAD Patients Moving to Improve Symptoms and QoL

News Daily News

AHA Scientific Statement: Get PAD Patients Moving to Improve Symptoms and QoL

January 03, 2019

Top News in Endovascular Therapy: 2018

News Features

Top News in Endovascular Therapy: 2018

December 28, 2018

New Appropriate Use Criteria for Peripheral Artery Interventions: A Multisociety Collaboration

News Daily News

New Appropriate Use Criteria for Peripheral Artery Interventions: A Multisociety Collaboration

December 18, 2018

Two Trials Halted in Wake of Study Linking Paclitaxel-Coated Devices to Deaths in PAD

News Daily News

Two Trials Halted in Wake of Study Linking Paclitaxel-Coated Devices to Deaths in PAD

December 17, 2018

Signal of Late Deaths With Paclitaxel-Coated DCBs and Stents for PAD Warrants Urgent Review, Authors Say

News Daily News

Signal of Late Deaths With Paclitaxel-Coated DCBs and Stents for PAD Warrants Urgent Review, Authors Say

December 07, 2018

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

News Conference News VIVA 2018

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

November 15, 2018

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

News Conference News VIVA 2018

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

November 13, 2018

IMPERIAL Substudy Provides Reassurance for Benefit of Eluvia in Long Lesions

News Conference News VIVA 2018

IMPERIAL Substudy Provides Reassurance for Benefit of Eluvia in Long Lesions

November 06, 2018

FDA Approves BioMimics 3D Stent for Femoropopliteal Artery Disease

News Daily News

FDA Approves BioMimics 3D Stent for Femoropopliteal Artery Disease

October 05, 2018

News Industry News

Veryan Medical receives PMA approval for BioMimics 3D

October 05, 2018

TCTMD’s Top 10 Most Popular Stories for September 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2018

October 02, 2018

Eluvia Gains FDA Approval Just Days After IMPERIAL Results Released

News Conference News TCT 2018

Eluvia Gains FDA Approval Just Days After IMPERIAL Results Released

September 24, 2018

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

News Conference News TCT 2018

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

September 22, 2018

12-Month Results From First-in-Human Randomized Study of Ranger DCB for Femoropopliteal Treatment

Presentation

12-Month Results From First-in-Human Randomized Study of Ranger DCB for Femoropopliteal Treatment

May 08, 2018

RANGER-SFA Data Support Another Paclitaxel-Coated Balloon for Superficial Femoral Artery Disease

News Daily News

RANGER-SFA Data Support Another Paclitaxel-Coated Balloon for Superficial Femoral Artery Disease

May 08, 2018

Same-Day Discharge After Peripheral Interventions Gets Mixed Results in Pilot Study

News Daily News

Same-Day Discharge After Peripheral Interventions Gets Mixed Results in Pilot Study

March 22, 2018

COMPASS Approach Helps With Leg Complications in Patients With PAD

News Conference News ACC 2018

COMPASS Approach Helps With Leg Complications in Patients With PAD

March 12, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.